ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients ...

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

EMA committee recommends marketing approval for Bayer’s Nubeqa for patients with advanced prostate cancer: Berlin Saturday, June 21, 2025, 10:00 Hrs [IST] The Committee for Medi ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the ...

Alicia Morgans, MD, MPH, discusses new data that shows darolutamide with ADT significantly improves quality of life and delays pain for patients with metastatic hormone-sensitive prostate cancer.

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

Prostate cancer often shows no early signs. An oncologist shares key symptoms men should watch for and treatment options that ...

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...

When you think of your penis shrinking, you might think of what happens after you’ve taken a cold shower or bath.

The Prostate Cancer Market is set to grow from USD 11.7 Billion in 2022 to USD 21.6 Billion by 2031, driven by rising cases in targeted therapies. The U.S. Prostate Cancer Market is expanding rapidly ...

Former President Joe Biden has been diagnosed with prostate cancer. Biden, 82, was diagnosed Friday, May 16, with prostate ...